What a Normal Denial Rate Looks Like in 2026

Initial claim denial rates have climbed across recent industry benchmarks. Benchmark roundups from RapidClaims and Aptarro put the current initial denial rate at around 11.8%, up from roughly 10.2% previously. On a base of 10%, that is a real jump in the share of claims coming back unpaid on first submission, and it has prompted a common question inside billing departments: does a rising number mean something in the practice's own process broke, or is this happening across the industry?

The available data points to an industry-wide shift. Payer audits, which often precede or accompany a denial, rose by roughly 30% year over year in 2025, according to industry benchmark aggregators that track claims activity. Prior-authorization-related denials rose by an estimated 31% across both commercial payers and Medicare Advantage plans over the same period. Neither figure describes one practice's coding habits or front-desk verification process. Both describe a change in how payers, broadly, are adjudicating and reviewing claims.

Why the rate differs so much by payer

A practice's overall denial rate is an average across its payer mix, and that average can hide more than it shows. MGMA's benchmarking data shows a real spread between individual payers: UnitedHealthcare's commercial denial rate has been reported at around 15.6%, notably higher than the rate reported for many other commercial and Medicare Advantage payers. A practice with a larger share of UnitedHealthcare patients will, all else equal, carry a higher blended denial rate than a practice with a smaller share, for reasons that have nothing to do with either practice's own performance.

The same pattern shows up outside the employer-sponsored insurance market. KFF's analysis of ACA marketplace plans tracks claims-denial and appeal patterns by insurer, and it also finds wide variation from one plan to the next. Across every data source that breaks results out by payer, rather than reporting a single market-wide figure, payer identity is one of the strongest predictors of denial rate. Practice quality matters, but it is one input among several, and often not the largest one.

Reason codes vary by payer too

Payers do not just deny at different rates, they deny for different reasons. One payer's most common denial reason might be missing prior authorization; another's might be timely filing or a bundling edit. A practice comparing its own reason-code distribution to a single aggregate benchmark, without separating results by payer, is comparing itself against a number built on a payer mix it may not share.

A rising rate is not automatically a verdict on the practice

Given how much of the increase is structural, a rising denial rate is not, by itself, evidence that a practice's billing operation is getting worse. Prior authorization requirements have expanded and tightened across commercial and Medicare Advantage plans, and the resulting rise in prior-authorization-related denials would show up in a practice's numbers even if every other part of its billing process stayed exactly the same. The same is true of the increase in payer audits: a practice that submits claims the same way it did last year can still see more of them flagged for review, simply because payers are reviewing more.

A rising rate still deserves attention. The more useful first question is how much the practice's own rate moved compared to how much the market-wide rate moved, not why the number changed in isolation. A practice whose denial rate rose from 9% to 10.5% in a year when the industry-wide rate rose from 10.2% to 11.8% moved in the same direction as the market, at a smaller magnitude. A practice whose rate rose from 9% to 15% over the same period has something happening that the market trend does not explain.

Reading your own rate against the benchmarks

A single aggregate denial rate, compared against a single aggregate benchmark, answers a narrower question than it appears to. A more useful comparison segments a practice's own data along at least three dimensions before comparing it to anything published:

• By payer. Calculate a denial rate for each payer separately and compare it to that payer's own reported benchmark where one exists, rather than to a blended market average. A practice's UnitedHealthcare rate should be read against UnitedHealthcare's reported average, not against the market-wide 11.8%.
• By denial reason. Separate prior-authorization denials, timely-filing denials, coding and bundling denials, and eligibility denials into their own categories. A practice with a rising prior-authorization denial rate but a flat rate on every other reason code is likely experiencing the industry-wide prior-authorization trend, not a breakdown somewhere else in the revenue cycle.
• By trend, not snapshot. A single month's rate is noisy, especially for a smaller practice with fewer total claims. A twelve-month rolling rate, tracked by payer and reason, separates a real shift from statistical noise.

This kind of segmentation matters because the alternative, tracking one aggregate number against one aggregate benchmark, tends to produce one of two mistakes. A practice with a heavy UnitedHealthcare or ACA marketplace share in its payer mix may assume its billing team is underperforming when its rate is actually in line with what that payer mix would predict. Or a practice with a real internal problem, sitting inside an otherwise favorable payer mix, may assume it is fine because its blended number still looks close to the published average.

The pressure behind the numbers

The stakes around reading this correctly have gone up. An August 2025 MGMA Stat poll found that 41% of medical group leaders name cost and margin pressure as their top operational concern, and 90% of groups report higher operating costs than the year before. Against that backdrop, a percentage point of denial rate that turns out to be avoidable, and that only shows up once a practice separates its numbers by payer and reason, is worth finding. A percentage point that turns out to track the broader market shift is worth knowing too, if only to stop treating it as an internal failure that needs fixing.

A practice can still act on the denials within its control: fixing documentation gaps, catching eligibility issues before the visit, and appealing claims that were wrongly denied. What changes is how a practice should judge whether its overall rate signals a problem in the first place. HFMA and MGMA's benchmark data describe a market moving in a particular direction. The more useful exercise for any single practice is figuring out how much of its own movement belongs to that market, and how much belongs to it.